Skip to content 
For researchers evaluating GHRP-2, the priority is documented compound identity, research-use-only labeling, and batch-specific analytical support. GHRP-2 is commonly associated with pralmorelin and growth hormone releasing peptide 2 in chemical and pharmacology databases, where it is classified as a peptide with documented molecular identity fields [1] , [2] . Laboratory buyers can compare these identity records with COA data, HPLC, LC-MS, lot traceability, and supplier documentation.
- GHRP-2 is a research peptide also indexed under pralmorelin and growth hormone-releasing peptide-2, with chemical identity fields available in official databases [1], [2].
- Published literature connects GHRP-2 with ghrelin receptor and growth hormone secretagogue receptor studies. These studies do not establish the performance of a particular catalog lot [2] , [3] .
- Research buyers should review the certificate of analysis, compound name, lot number, purity data, and analytical testing documentation before procurement.
- HPLC can support peptide purity review, while LC-MS and mass spectrometry can support identity and impurity characterization when paired with suitable reference data [4], [5].
Fast Answer: What Should Researchers Check Before They Buy GHRP-2 for Research?
Researchers looking to buy GHRP-2 for research should first confirm RUO labeling, product-page identity fields, a batch-specific certificate of analysis, and analytical testing documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Review COA, HPLC, LC-MS, lot number, and storage notes before any research procurement decision.
What Documentation Should Come First?
The first review layer should be the product identity record: compound name, recognized synonyms, molecular formula, and supplier documentation. PubChem lists pralmorelin with molecular formula C45H55N9O6 and molecular weight of about 818.0 g/mol, while IUPHAR identifies pralmorelin as GHRP-2 and growth hormone-releasing peptide-2 [1], [2].
After identity fields, research buyers should review the batch-specific certificate of analysis. A COA should be read as a documentation record, not as a claim about research outcomes.
Why RUO Labeling Matters Before Procurement
RUO labeling identifies the material as intended for laboratory research, not human or veterinary use.
Endocrine-pathway literature may describe findings in specific experimental systems. Those findings do not establish the suitability of a research-use-only material for other uses.
What Is GHRP-2 in Research Literature?
GHRP-2 is a synthetic peptide commonly cross-referenced with pralmorelin, KP-102, and growth hormone releasing peptide 2 in database and pharmacology sources [1], [2]. IUPHAR classifies pralmorelin as a peptide and describes it as an analogue that activates the growth hormone secretagogue, or ghrelin, receptor [2].
Research literature places GHRP-2 in the broader category of growth hormone secretagogues and ghrelin receptor research. This classification helps researchers locate relevant sources; it does not establish product suitability.
GHRP-2 as a Synthetic Hexapeptide in Literature
A peer-reviewed analytical report describes pralmorelin/GHRP-2 with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, which places it in the synthetic hexapeptide category [6]. Sequence documentation can help laboratory buyers compare the product page, COA, and published literature.
Amino acid sequence is not the same as complete material verification. For procurement review, the sequence should align with the COA, identity testing, and lot-specific records.
Where Does Pralmorelin Fit in Compound Naming?
Pralmorelin is the database and pharmacology name commonly associated with GHRP-2 [1], [2]. IUPHAR lists GHRP-2, growth hormone-releasing peptide-2, and KP-102 as synonyms for pralmorelin [2].
Naming consistency matters because product pages, literature abstracts, COAs, and analytical reports may use different labels for the same compound. A research buyer should confirm that those labels point to the same target compound before comparing documentation.
What Related Endocrine Research Adds
Related endocrine research connects GHRP-2 with ghrelin, GHSR, GHRH, and pituitary pathways. Ghrelin was identified as an endogenous ligand for the growth hormone secretagogue receptor, and receptor-focused literature connects ghrelin signaling with pituitary and hypothalamic research models [7], [8].
That context supports literature interpretation, but does not establish a catalog product’s effects.
What Does Research Use Mean for Growth Hormone Releasing Peptide 2?
Research-use-only GHRP-2 is a laboratory material evaluated through documentation, analytical testing, and relevant literature. It is not intended for personal or clinical use.
How Laboratory Research Differs From Non-Research Use
Laboratory research evaluates defined models and analytical questions using documented materials and methods. Research-use-only materials are not supplied for personal or clinical use.
Receptor and Pathway Context in Related Research
GHRP-2 appears in ghrelin receptor and growth hormone secretagogue receptor literature. IUPHAR identifies GHRP-2, GHRP-6, and hexarelin as synthetic peptide agonists for the ghrelin receptor [3] .
That receptor context supports literature interpretation. It does not establish product claims for RUO materials.
Growth Hormone Secretagogue Receptor Context
The growth hormone secretagogue receptor, also called the ghrelin receptor, is a G protein-coupled receptor connected to ghrelin signaling [3], [10]. UniProt identifies human GHSR as a receptor for ghrelin and notes coupling to G-alpha proteins in receptor function context [10].
Ghrelin Receptor Agonist Classification
IUPHAR’s ghrelin receptor page places GHRP-2 among synthetic peptide agonists for the receptor [3] . This classification describes receptor pharmacology, not the verified performance of a supplier’s lot.
Why Is Pathway Relevance Not a Product Claim?
Pathway relevance means a compound appears in literature related to a receptor, signaling cascade, or model system. It does not mean a listed research material has demonstrated any product effect.
This boundary is essential for endocrine pathway research.
How Should Published Literature Be Interpreted?
Published literature should be interpreted by model type, endpoint, source quality, and RUO relevance. A receptor assay, database record, review article, or preclinical paper may provide context, but each evidence type has limits.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Pralmorelin/GHRP-2 names, formula, and database identifiers [1], [2] | Official database | Useful for identity cross-checking, not outcome claims |
| Receptor context | Ghrelin receptor and growth hormone secretagogue receptor mapping [3], [10] | Pharmacology database | Useful for pathway classification |
| Endocrine pathway literature | GHRH, pituitary gland, and anterior pituitary signaling context [11], [12] | Academic and database context | Useful for interpreting related receptor studies |
| Peptide analytical review | HPLC separation and LC-MS characterization of synthetic peptides [4], [5] | Analytical literature | Useful for purity and identity review |
What Can Published Literature Support?
Published literature can support compound classification, receptor context, analytical concepts, and model-specific interpretation. Ghrelin discovery literature explains the endogenous ligand context for GHSR, while GHRP literature examines synthetic growth hormone-releasing peptides [7] , [13] .
Published literature should not be used as a shortcut for product claims.
How Does Preclinical Context Shape Interpretation?
Preclinical context helps explain why some studies examine signaling, pituitary models, receptor interactions, or endocrine endpoints. A study of pituitary somatotroph cells examined whether GHRP-2 had a direct growth hormone-releasing, GHRH-independent action in that model [14].
Model-specific findings apply to the experimental materials and conditions studied; they do not establish the performance of a catalog product.
Limits of Research Evidence
Reported effects of GHRP-2 depend on the study design, experimental materials, and model. Findings cannot be assumed to apply to a different preparation or setting.
Some published literature outside the scope of RUO product use has examined this compound class in human study settings, including growth hormone deficiency as a clinical research category [15]. That literature should not be interpreted as a use claim for research-use-only materials.
How Research Findings Stay Separate From Product Claims
A research finding belongs to its study design, methods, materials, and model.
What Does RUO Documentation Establish?
RUO documentation helps researchers evaluate compound identity, analytical support, and lot traceability. It does not establish suitability for non-research use.
How Should Endocrine Findings Be Interpreted?
Findings about GH secretion, pituitary signaling, or growth hormone release describe the particular models and endpoints examined in the cited literature [11] , [14] . They do not establish effects or safety for this catalog product.
Why Should Certificate of Analysis Review Come Before Procurement?
A certificate of analysis should come before procurement because it links a product listing to batch-specific analytical information. For a research peptide, the COA should help confirm identity fields, purity data, lot number, testing method, and date of analysis.
This does not make the COA a complete scientific proof. It makes it a critical documentation checkpoint.
What Should a Certificate of Analysis Identify?
A certificate of analysis should identify the compound, batch or lot number, testing method, and reported analytical results. FDA analytical guidance emphasizes the role of validated analytical procedures and the selection of suitable validation tests for analytical methods [16].
For peptide research materials, a COA is most useful when it can be matched to the product page and lot-specific documentation. The document should not be treated as interchangeable across batches.
How Do Researchers Review COA Consistency?
Researchers can review COA consistency by comparing the compound name, molecular weight, lot number, purity method, and identity method across documents. FDA analytical-method guidance discusses the importance of reference standards, qualification records, certificates of analysis, and impurity profile information in analytical contexts [17].
The practical question is whether the product page, COA, and label tell the same documentation story. If they do not, the material needs closer review.
Why Do Batch-Specific COA Dates Matter?
COA dates matter because research procurement is batch-specific. A COA from a different lot does not confirm the documentation status of the material being reviewed.
Data integrity guidance for regulated laboratories emphasizes complete laboratory records, including graphs, charts, spectra, notebooks, worksheets, and instrument data where applicable [18]. That principle supports careful review of batch-level records.
Peptide Purity and Identity Testing Considerations
Peptide purity and identity are related, but they are not the same. Purity testing may show the relative proportion of a main chromatographic peak, while identity testing helps confirm whether that material corresponds to the intended peptide.
A neutral lab-test verification workflow can support review:
- Verify the compound name, synonym set, and lot number across the product page, label, and COA.
- Review the batch-specific certificate of analysis.
- Check whether the purity testing method is identified.
- Confirm whether identity testing is supported by LC-MS, mass spectrometry, or another suitable analytical method.
- Review chromatogram, retention-time, or mass data when available.
- Check the COA date and laboratory source.
- Record storage and handling documentation in the laboratory file.
How Assay Purity Supports Material Review
Assay purity supports material review by showing how an analytical method reports the primary component relative to other detected components. HPLC is widely used in peptide analysis and purification because it can separate peptide components using chromatographic conditions suited to peptide chemistry [4].
A purity value should be read with the method and chromatogram in mind. It does not replace identity confirmation.
What Identity Confirmation Adds to Procurement
Identity confirmation adds confidence that the material corresponds to the intended compound. LC-MS is often used in synthetic peptide characterization because mass spectrometry can help evaluate structural features and impurities when paired with liquid chromatography [5].
Mass spectrometry is well suited for synthetic peptide identity and purity analysis when the expected sequence and mass are known [19]. For procurement review, identity confirmation should connect back to the COA and lot record.
HPLC and LC-MS Documentation for GHRP-2
HPLC and LC-MS documentation should be read as complementary. HPLC can support purity review, while LC-MS can support identity and impurity characterization [4], [5].
For GHRP-2, a strong documentation set may include HPLC purity data, LC-MS identity data, compound name, formula, molecular weight, lot number, and COA date. The value comes from the consistency of the documentation stack.
How Does HPLC Support Peptide Purity Review?
HPLC supports peptide purity review by separating peptide components so that chromatographic peaks can be assessed. Peptide HPLC methods can include reversed-phase, ion-exchange, and size-exclusion modes depending on the analytical objective [4].
For a product-page buyer, the key is not to overread a purity percentage. The key is to confirm the method, batch link, and supporting chromatogram.
How Does LC-MS Support GHRP-2 Identity Verification?
LC-MS supports GHRP-2 identity verification by combining liquid chromatography with mass-based analysis. LC-MS can help characterize synthetic peptide impurities, including structurally related forms, when the method is appropriate for the peptide and analytical question [5].
For documentation review, LC-MS data should be connected to the same lot as the COA. Otherwise, the data may not support the specific material being evaluated.
Why Does Mass Spectrometry Data Help Confirm Identity?
Mass spectrometry data helps confirm identity because peptide mass and fragmentation information can be compared with expected peptide features. Synthetic peptide mass spectrometry is often discussed as a tool for evaluating identity and purity when sequence expectations are known [19].
For GHRP-2, review mass data alongside the expected molecular weight and sequence, and confirm that the evidence applies to the lot under evaluation.
Lot Traceability and Batch-Specific Documentation
Lot traceability ties the material listing to a specific batch record. It helps research buyers avoid treating generic documentation as if it applied to every material unit.
OECD guidance on GLP test items emphasizes the importance of identification, labeling, storage, characterization, and handling records for test items used in GLP studies [20]. RUO procurement can apply the same documentation mindset without suggesting the material is intended for regulated study use.
What Do Lot Numbers Add to Traceability?
Lot numbers make documentation specific. They connect the product label, COA, test records, and storage notes to a defined batch.
Without lot-level alignment, a COA may be informative but incomplete. The stronger review asks whether every document points to the same lot.
How Batch Documentation Supports Research Procurement
Batch documentation supports research procurement by reducing ambiguity. It gives laboratory buyers a record of what was tested, when it was tested, and which lot the record describes.
FDA Q7A guidance states that quality systems are intended to help ensure materials meet the quality and purity characteristics they are represented to possess [21] . Research buyers can review whether supplier records substantiate the identity and analytical characteristics reported for a lot.
Which Supplier Documentation Matters Before Researchers Buy GHRP-2 for Research?
Before researchers buy GHRP-2 for research, supplier documentation should answer identity, purity, testing, lot traceability, and labeling questions.
The strongest documentation stack includes the product listing, batch-specific COA, analytical testing summary, lot number, storage notes, and RUO statement. Each part should support the same compound identity.
What Should Research Buyers Compare Across Suppliers?
Research buyers should compare document clarity, not marketing claims. Useful comparison points include COA availability, HPLC method visibility, LC-MS identity support, lot-specific records, and consistent RUO labeling.
This is a source-quality filter: official databases and peer-reviewed literature support scientific context, while supplier documents support procurement review. The two should not be merged into product claims.
How Third-Party Testing Fits the Documentation Stack
Third-party testing can add value when the lab source, method, lot number, and date are clearly documented. It is less useful when the report is generic or detached from the material being evaluated.
Analytical documentation is strongest when it is traceable. The record should show what was tested and how the report connects to the product page.
Storage, Handling, and Labeling Documentation Review
Storage, handling, and labeling documentation help preserve the integrity of laboratory records. They also clarify how the supplier frames the material.
OECD test-item guidance includes storage, labeling, identification, and characterization among test-item management considerations [20]. For RUO procurement, those fields support orderly lab documentation.
Why Lyophilized Material Notes Matter
Lyophilized material notes matter because freeze drying is a process used to remove water from a frozen material by sublimation and desorption, and storage conditions can affect material stability [22].
For research buyers, the key question is whether storage expectations are documented and consistent. Storage notes belong in the laboratory record.
What Labeling Consistency Shows Across Documentation
Labeling consistency shows whether the supplier’s product page, COA, and product label identify the same compound. For GHRP-2, the label should align with the canonical compound name and recognized synonyms.
Consistency does not replace analytical testing. It helps prevent ambiguity before the laboratory reviews COA and method data.
What Should Final Procurement Review Confirm Before Researchers Buy GHRP-2 for Research?
Final procurement review should confirm RUO labeling, consistent compound identity, and a complete set of lot-specific documentation. Published findings and supplier claims do not replace analytical records for the material being evaluated.
This final review is not about product outcomes. It is about whether a research buyer has enough documentation to evaluate the listing.
What Should Researchers Confirm Before Procurement?
Use this quality and documentation checklist:
- Verify that GHRP-2 is labeled for research use only.
- Review the batch-specific certificate of analysis.
- Confirm that purity data are supported by analytical testing.
- Check that the lot number on the COA matches the product documentation.
- Compare compound name, synonyms, molecular weight, and sequence across records.
- Distinguish published research findings from evidence about the supplied lot.
- Document storage and labeling details in the laboratory record.
How Documentation Review Reduces Ambiguity
Documentation review reduces ambiguity by making each claim checkable. A product name can be compared with a database record, a COA can be matched to a lot, and analytical data can be reviewed next to the stated testing method.
For GHRP-2, this process is especially helpful because literature may use multiple names: GHRP-2, pralmorelin, KP-102, and growth hormone-releasing peptide-2 [2]. Consistent naming improves procurement clarity.
Where Pure Lab Peptides Fits in RUO Procurement
Research buyers can use the available Pure Lab Peptides product records to compare compound identity, analytical documentation, and RUO labeling.
The safest next step is documentation-first evaluation. Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
Common Misunderstandings in GHRP-2 Research Procurement
Several distinctions matter when evaluating GHRP-2 research materials:
- Published literature does not equal product-use guidance.
- A purity percentage does not prove complete peptide identity; HPLC and LC-MS answer different analytical questions [4], [5].
- A COA should be batch-specific, not generic.
- Receptor pathway relevance is not a product claim.
The safest interpretation is documentation-first.
Next Steps for RUO Documentation Review
Review batch-specific documentation before selecting any research-use-only peptide. For research teams comparing peptide suppliers, prioritize COA availability, transparent labeling, analytical testing, and lot-level documentation. Explore Pure Lab Peptides for RUO peptide compounds with research-focused product information and available documentation.
FAQs
What is another name for GHRP-2?
Another name for GHRP-2 is pralmorelin, and published database records also associate it with growth hormone-releasing peptide-2 and KP-102 [1] , [2] . Synonym review helps laboratory buyers compare product identity fields, COA records, and peptide sequence references for consistent compound identification.
Is GHRP-2 a growth hormone?
GHRP-2 is not itself growth hormone; it is classified in research literature as a peptide associated with growth hormone secretagogue receptor studies [2], [3].
What should researchers consider before they buy GHRP-2 for research?
Researchers should consider documentation before they buy GHRP-2 for research. Key review points include RUO labeling, batch-specific COA data, lot traceability, peptide identity, and analytical testing records. If available, HPLC and LC-MS documentation can help connect purity review and identity confirmation to the same research material lot [4], [5].
What does the peptide sequence show for GHRP-2 research materials?
The peptide sequence helps identify GHRP-2 as a defined synthetic hexapeptide in research literature [6]. Sequence review can support compound characterization when paired with molecular weight, synonym checks, COA data, and analytical testing. It should not be treated as complete verification by itself because batch-specific documentation remains necessary.
How do high-performance liquid chromatography and LC-MS support documentation review?
High-performance liquid chromatography supports peptide purity review by separating components for chromatographic assessment, while LC-MS supports identity review through mass-based analytical data [4], [5]. For GHRP-2 research materials, these methods are most useful when linked to the same lot number, COA, and supplier documentation. Method context matters as much as the reported value.
How should researchers interpret GHSR-1A receptor and cell signaling language?
GHRP-2 appears in research discussions involving ghrelin agonist activity, receptor signaling, and signal transduction pathways [3] . GHSR-1A receptor and cell signaling findings describe the experimental systems studied, not verified effects of a supplier’s product.
Researchers Cited in This Guide
The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.
Masayasu Kojima
Author profile: KAKEN Researcher Profile
Masayasu Kojima’s published work contributes to the ghrelin and growth hormone secretagogue receptor literature. His publications provide background on peptide ligands, receptor identification, and endocrine pathways, supporting interpretation of compound classification and receptor studies within their experimental limitations.
Selected publications:
- Ghrelin is a growth-hormone-releasing acylated peptide from stomach — Nature, 1999. DOI: 10.1038/45230. PMID: [10604470]
- Ghrelin: structure and function — Physiological Reviews, 2005. DOI: 10.1152/physrev.00012.2004. PMID: [15788704]
Yuxiang Sun
Author profile: Texas A&M University Profile
Yuxiang Sun’s publications contribute to GHSR and ghrelin receptor pathway research. Her receptor-focused studies provide background for understanding endocrine pathways in the experimental models investigated.
Selected publications:
- A PNAS study relevant to GHSR pathway research — Proceedings of the National Academy of Sciences, 2004. DOI: 10.1073/pnas.0305930101. PMID: [15070777]
- A publication examining ghrelin receptor expression in preclinical endocrine research — Endocrinology, 2007. DOI: 10.1210/en.2006-0782
REFERENCES
- National Library of Medicine. Pralmorelin compound record. PubChem. Updated database record.
- IUPHAR/BPS Guide to Pharmacology. Pralmorelin ligand record. Guide to Pharmacology Database.
- IUPHAR/BPS Guide to Pharmacology. Ghrelin receptor record. Guide to Pharmacology Database.
- Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007.
- Lian Z, et al. LC-MS characterization of synthetic peptides. Journal of the American Society for Mass Spectrometry. 2021. PMID: 34110145.
- Okano M, et al. Analytical identification of pralmorelin/GHRP-2. Rapid Communications in Mass Spectrometry. 2010. PMID: 20552695.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin discovery and GHSR ligand context. Nature. 1999. PMID: 10604470. DOI: 10.1038/45230.
- Howard AD, Feighner SD, Cully DF, et al. Growth hormone secretagogue receptor discovery study. Science. 1996. PMID: 8688086.
- European Bioinformatics Institute. Pralmorelin compound record. ChEMBL.
- UniProt Consortium. GHSR human protein record. UniProtKB.
- Olarescu NC, et al. Normal physiology of growth hormone in adults. Endotext, NCBI Bookshelf. Updated 2025.
- National Library of Medicine. Growth Hormone-Releasing Hormone MeSH record. NCBI MeSH.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides research review. European Journal of Endocrinology. 1997. PMID: 9186261.
- Peroni CN, et al. GHRP-2 research in pituitary somatotroph cell context. Growth Hormone & IGF Research. 2012.
- Adis International. Pralmorelin source profile. Drugs in R&D. 2004. PMID: 15230633.
- U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance. 2024.
- U.S. Food and Drug Administration. Analytical procedure content and reference material guidance. FDA Guidance. 2015.
- U.S. Food and Drug Administration. Data integrity and laboratory record guidance. FDA Guidance. 2018.
- Prabhala BK, et al. Mass spectrometry characterization of synthetic peptides. Methods in Molecular Biology. 2015. PMID: 26424265.
- OECD. Management, characterisation and use of test items used in GLP studies. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. 2018. DOI: 10.1787/da9ee953-en.
- U.S. Food and Drug Administration. Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. FDA Guidance.
- Roy I, Gupta MN. Freeze-drying process review for protein and peptide materials. Biotechnology and Applied Biochemistry. 2004. PMID: 15032737.
Research Disclaimer
This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.
There are no reviews yet.